While further roles for FOXC1 in Luminal B breast cancers may include modulation of hormone receptor status and therapeutic response, our observations strongly suggest that any such pro-tumour effects of FOXC1 expression in Luminal B patients, if they occur, are overridden by the anti-metastatic function of FOXC1, leading to an overall pro-survival effect in Luminal B patients expressing higher FOXC1 levels (Refer to figures). The gene discussed is NR4A1; the disease is neoplasm.